Aktiesnakken — November 2010
-
Der er Neurosearch telefon konference her kl 11. Jeg dækker den live i IR-Live
-
----------------------Neuroserarch Q3 CC--------------
-
Man kan følge slides her http://webcast.zoomvision.se/denmark/clients/neurosearch/10_386/frameset.php?live.asx&&9&audio
-
Den nye ceo Pastrik Dahlen fortæller godt hvor glad han er for at være kommet til Neurosearch
-
Han er stadig i hans "100 dages vindue" så det er for tidligt at komme med evt nye strategier
-
Nu gennemgang af regnskanb
-
289 mio i udgifter
-
52 mio i oms
-
de forventer lidt højere udgiofter i Q4 hvorfor de stadig fastholder guidens
-
Huntexil: signifikant effekt fra det amerikanske studie i TMS (sekundær endpoint)
-
Topsil fastholder
-
primære endpoint mms viste en "stærk positiv trend" men missede signifikans
-
favorable langtids safty data (12 mdr)
-
De vil i Q1 tale med myndighederne om hvordan de kan få stoffet godkendt hurtigst muligt
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind